Company

Ascletis Pharma (China) Co.

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · PHASE 3 TRIAL

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

ClinicalTrials.gov

This is a clinical trial registry record with no reported results; the study is actively recruiting and outcomes have not yet been assessed or published.

PreliminaryObesity Ascletis Pharma (China) Co.Overweight

Reported

Estimated sample size1560

Primary outcome measurePercent change from baseline in body weight…

Study phasePHASE 3

AUG 14, 2026 · PHASE 3 TRIAL

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

ClinicalTrials.gov

This is a clinical trial registry record with no reported results; the study is actively recruiting and outcomes have not yet been analysed or posted.

PreliminaryObesity Ascletis Pharma (China) Co.Overweight

Reported

Estimated enrollment3003

Primary outcome measurePercent change in body weight from baseline…

Study phasePhase 3